A clinical study found the topical reduced wrinkles, improved smoothness, and lifted skin by up to 18% in 12 weeks.
SkinCeuticals announced the launch of the latest product in its A.G.E. line, A.G.E. Interrupter Ultra Serum, geared toward individuals looking for non-invasive treatments or an adjunct to in-office procedures to address sagging skin.
In a US clinical study on all skin tones, the A.G.E. Interrupter Ultra Serum demonstrated visible improvements across multiple key indicators of aging. The serum lifts skin by up to 18%, reduces wrinkles by up to 16%, and improves skin smoothness by up to 54% in 12 weeks.1
“A.G.E. Interrupter Ultra Serum is incredibly effective and clinically proven to deliver visible lifting and tightening results on its own. When paired with existing SkinCeuticals product A.G.E. Interrupter Advanced Cream and an ultrasound procedure, patients can expect visible improvements to their skin laxity,” says Julie Woodward, MD, oculofacial plastic surgeon, in a release.
A.G.E. Interrupter Ultra Serum is designed to address visible signs of aging linked to collagen loss and glycation. It is engineered with double-patented technology and formulated with a 34.6% concentration of flavo-proxylane, rhamnose, and gentiana lutea root extract.
A.G.E. Interrupter Ultra Serum also is formulated to complement lifting ultrasound procedures and proven to work synergistically within regimens that include A.G.E. Interrupter Advanced Cream, including use among GLP-1 patients. New clinical testing shows when A.G.E. regimen is paired with ultrasound on GLP-1 patients, it visibly reduces skin laxity by -20%.2
The product is available online and via partner skincare professionals nationwide for $185.
Photo caption: Clinical testing shows A.G.E. Interrupter Ultra Serum improves sagging skin.
Photo credit: SkinCeuticals
References
- Clinical testing of 76 non-GLP-1 subjects after 12 weeks showed up to: +18% visible lifting, -16% global wrinkles, and +54% smoothness and average results of +7.6% lifting, -7.6% global wrinkles, and +40% smoothness improvement across all 76 subjects. Shown in testing to be well tolerated by GLP-1 users. Results shown here were not tested on GLP-1 users.
- A 12-week, double-blind, randomized, controlled, split-face and split-neck clinical study investigated the effects of a flavo-proxylane regimen compared to a control regimen on 25 patients, who were also undergoing GLP-1 treatments. The study assessed skin quality, aging signs, and treatment tolerance at multiple time points before and after a single ultrasound treatment.
